Elanco Animal Health (ELAN) Accumulated Expenses (2017 - 2025)
Elanco Animal Health (ELAN) reported Accumulated Expenses of $206.0 million for Q4 2025, up 16.38% on a YoY basis from $177.0 million in Q4 2024, and up 16.38% sequentially from $177.0 million in Q4 2024.
Elanco Animal Health (ELAN) Accumulated Expenses (2017 - 2025) Analysis & Trends
Elanco Animal Health (ELAN) has 9 years of Accumulated Expenses data on file, last reported at $206.0 million in Q4 2025.
- For the quarter ending Q4 2025, Accumulated Expenses rose 16.38% year-over-year to $206.0 million; the trailing twelve-month figure through Dec 2025 stood at $206.0 million (up 16.38% YoY), and the FY2025 full-year result was $206.0 million, up 16.38% from the prior year.
- Accumulated Expenses improved to $206.0 million in Q4 2025, from $177.0 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $206.0 million in Q4 2025 to a low of $110.0 million in Q1 2023.
- A 5-year average of $144.8 million and a median of $141.0 million in 2022 frame the typical range for Accumulated Expenses.
- Across the five-year window, Accumulated Expenses jumped 116.78% in 2021 and decreased 21.08% in 2022, its largest moves.
- Tracing ELAN's Accumulated Expenses over 5 years: stood at $185.0 million in 2021, then fell by 21.08% to $146.0 million in 2022, then gained by 7.53% to $157.0 million in 2023, then advanced by 12.74% to $177.0 million in 2024, then advanced by 16.38% to $206.0 million in 2025.
- Business Quant data shows ELAN's Accumulated Expenses at $206.0 million in Q4 2025, $177.0 million in Q4 2024, and $157.0 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 206.00 Mn |
| Dec 31, 2024 | 177.00 Mn |
| Dec 31, 2023 | 157.00 Mn |
| Mar 31, 2023 | 110.00 Mn |
| Dec 31, 2022 | 146.00 Mn |
| Sep 30, 2022 | 136.00 Mn |
| Jun 30, 2022 | 113.00 Mn |
| Mar 31, 2022 | 111.00 Mn |
| Dec 31, 2021 | 185.00 Mn |
| Sep 30, 2021 | 159.00 Mn |
| Jun 30, 2021 | 124.00 Mn |
| Mar 31, 2021 | 114.00 Mn |
| Dec 31, 2020 | 144.00 Mn |
| Sep 30, 2020 | 139.90 Mn |
| Jun 30, 2020 | 57.20 Mn |
| Mar 31, 2020 | 56.20 Mn |
| Dec 31, 2019 | 99.60 Mn |
| Sep 30, 2019 | 88.80 Mn |
| Jun 30, 2019 | 67.30 Mn |
| Mar 31, 2019 | 64.20 Mn |